Apart from the ongoing focus on trading activities in the past, it might finally pay to look forward to what is shaping up as possible milestones for funding arrangements for Anteo.
Jef has dropped some hints in the latest update, which I find rather interesting.
As previously mentioned, market and HC alike are fixated on funding arrangements for the EO while I believe Jef has given some details worthwhile to look at in regards to the presentation in China this week.
Anteo Group CEO Dr Jef Vangenechten said, “The technical presentation by Anteo will be critical for visibility in the Chinese IVD sector, and will help to progress business development activities underway regarding distribution of Anteo products in China.”
1,
Why does the presentation in China warrant an announcement in the first place, when one poster here rightly wrote that the Egyptian deal of nearly 2 million dollars was a side note within another update?
IMHO, there is a concept behind such reporting, pointing at future developments in the area which could be meaningful for funding.
To present in conjunction with Merck still holds my interest in terms of funding outlook for ADO.
2,
Why is Anteo presenting and why is it 'critical' for Chinese IVD markets?
As we know, Diasource has ongoing distribution plans in China, why was Anteo invited and why is it critical that IVD companies there see our technology presented at this point in time?
3,
Business developments under way, again, was so far only pointing at further Dia interest in the area.
One would suspect our CEO is planning a roll out of products containing our technology.
I had long suspected that Jef would circumvent the sluggish European arena for a more dynamic and innovation oriented Asian market penetration of Anteo's technology.
Philips was a clear indicator of a slow moving and difficult market in regards to innovation.
The Chinese might be more forthcoming to revolutionize their sector.
4,
Anteo's products in China, not technology, testing and the like, but final products.
Are we further down the line to releasing products in the Asian financial capital than we are aware?
Has Merck and its Chinese partner in conjunction with Dia enabled a roll out allowing financial backing of our Australian entity?
It would make sense, in my opinion, if that point towards the expected liquidity event.
Expand
